Status:
COMPLETED
Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation
Lead Sponsor:
Herlev and Gentofte Hospital
Conditions:
Latent Tuberculosis
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study will be investigating the effect of latent tuberculosis infection (LTBI) treatment on glucose tolerance and low-grade inflammation. Almost a century ago, researchers proposed that diabetes ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Inclusion criteria for the LTBIDM arm:
- 18+ years
- Known DM type 2
- Inclusion criteria for LTBI arm
- 18+ years
- LTBI positive
- No diagnosis with or known DM (1 and 2)
- Exclusion Criteria (both arms) :
- Previous treatment for TB or LTBI
- Pregnancy
- Type 1 DM
- Known immunosuppression such as: HIV, steroid treatment within 14 days before inclusion, daily NSAID treatment, ongoing chemotherapy, ongoing immunomodulating treatment or splenectomy
- Known contraindication to both study drugs
- Known active liver disease
- Known severe inflammatory or rheumatological diseases with immune activation and need for prolonged systemic treatment such as IBD, RA, Psoriasis and Wegners granulomatosis
- Recent antibiotic treatment (\>2 days) or severe infection within 14 days before enrollment
- Known active cancer
Exclusion
Key Trial Info
Start Date :
April 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2023
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT04830462
Start Date
April 15 2021
End Date
May 1 2023
Last Update
May 16 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Herlev-Gentofte Hospital
Copenhagen, Denmark